Glaukos
Market Cap
US$1.3b
Last Updated
2020/04/04 06:33 UTC
Data Sources
Company Financials +
Executive Summary
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has Glaukos's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GKOS's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-12.4%
GKOS
0.08%
US Medical Equipment
-2.0%
US Market
1 Year Return
-62.6%
GKOS
-7.1%
US Medical Equipment
-15.1%
US Market
Return vs Industry: GKOS underperformed the US Medical Equipment industry which returned -7.1% over the past year.
Return vs Market: GKOS underperformed the US Market which returned -15.1% over the past year.
Shareholder returns
| GKOS | Industry | Market | |
|---|---|---|---|
| 7 Day | -12.4% | 0.08% | -2.0% |
| 30 Day | -26.8% | -13.7% | -19.7% |
| 90 Day | -46.4% | -18.1% | -23.2% |
| 1 Year | -62.6%-62.6% | -6.3%-7.1% | -13.4%-15.1% |
| 3 Year | -43.3%-43.3% | 42.4%38.5% | 10.9%3.7% |
| 5 Year | n/a | 71.1%53.4% | 28.4%14.4% |
Price Volatility Vs. Market
How volatile is Glaukos's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Is Glaukos Corporation's (NYSE:GKOS) 2.3% ROE Worse Than Average?1 month ago | Simply Wall St
Should You Worry About Glaukos Corporation's (NYSE:GKOS) CEO Salary Level?2 months ago | Simply Wall St
Glaukos (NYSE:GKOS) Shareholders Have Enjoyed A 29% Share Price GainValuation
Is Glaukos undervalued compared to its fair value and its price relative to the market?
70.74x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GKOS ($29.21) is trading above our estimate of fair value ($16.62)
Significantly Below Fair Value: GKOS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GKOS is poor value based on its PE Ratio (70.7x) compared to the Medical Equipment industry average (37.5x).
PE vs Market: GKOS is poor value based on its PE Ratio (70.7x) compared to the US market (12.4x).
Price to Earnings Growth Ratio
PEG Ratio: GKOS is poor value based on its PEG Ratio (3x)
Price to Book Ratio
PB vs Industry: GKOS is good value based on its PB Ratio (1.9x) compared to the US Medical Equipment industry average (2.9x).
Next Steps
Future Growth
How is Glaukos forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
23.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GKOS's forecast earnings growth (23.4% per year) is above the savings rate (1.7%).
Earnings vs Market: GKOS's earnings (23.4% per year) are forecast to grow faster than the US market (13.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GKOS's revenue (14.8% per year) is forecast to grow faster than the US market (7.1% per year).
High Growth Revenue: GKOS's revenue (14.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GKOS's Return on Equity is forecast to be low in 3 years time (6.8%).
Next Steps
Past Performance
How has Glaukos performed over the past 5 years?
30.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GKOS has a large one-off loss of $32.3M impacting its December 31 2019 financial results.
Growing Profit Margin: GKOS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: GKOS has become profitable over the past 5 years, growing earnings by 30.8% per year.
Accelerating Growth: GKOS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: GKOS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).
Return on Equity
High ROE: GKOS's Return on Equity (2.3%) is considered low.
Next Steps
Financial Health
How is Glaukos's financial position?
Financial Position Analysis
Short Term Liabilities: GKOS's short term assets ($262.9M) exceed its short term liabilities ($57.7M).
Long Term Liabilities: GKOS's short term assets ($262.9M) exceed its long term liabilities ($87.4M).
Debt to Equity History and Analysis
Debt Level: GKOS is debt free.
Reducing Debt: GKOS currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Inventory Level: GKOS has a low level of unsold assets or inventory.
Debt Coverage by Assets: GKOS's debt is covered by short term assets (assets are 1.8498394731936E+16x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GKOS is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: GKOS is profitable, therefore cash runway is not a concern.
Next Steps
Dividend
What is Glaukos's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GKOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate GKOS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GKOS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GKOS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GKOS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.2yrs
Average management tenure
CEO
Thomas Burns (58yo)
18.08s
Tenure
US$5,198,717
Compensation
Mr. Thomas William Burns has been the Chief Executive Officer and President at Glaukos Corporation since March 2002. He serves as Director of Avedro, Inc. since November 21, 2019. He served as Director of ...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD5.20M) is about average for companies of similar size in the US market ($USD4.73M).
Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 18.08yrs | US$5.20m | 2.5% $31.9m | |
| CFO & Senior VP of Corporate Development | 2.92yrs | US$1.95m | 0.024% $302.1k | |
| Chief Operating Officer | 3.17yrs | US$1.96m | 0.35% $4.5m | |
| Co-Founder | no data | no data | no data | |
| Director of Investor Relations | no data | no data | no data | |
| Senior VP | 4.83yrs | no data | no data | |
| Senior Vice President of Human Resources | 4.92yrs | no data | no data | |
| Senior Vice President of New Technologies | 3.17yrs | no data | no data | |
| Chief Medical Officer | 3.17yrs | no data | no data | |
| Senior Vice President of Corporate Strategy & Business Development | 2yrs | no data | no data |
3.2yrs
Average Tenure
58yo
Average Age
Experienced Management: GKOS's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 18.08yrs | US$5.20m | 2.5% $31.9m | |
| Independent Chairman of the Board | 18.83yrs | US$264.99k | 0.11% $1.4m | |
| Director | 0.083yr | US$224.99k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.75yrs | US$224.99k | 0.025% $315.7k | |
| Independent Director | 5.75yrs | US$234.99k | 0.011% $135.3k | |
| Independent Director | 5.75yrs | US$232.48k | 0.018% $231.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 5.75yrs | US$243.99k | 0.020% $250.4k |
5.8yrs
Average Tenure
59yo
Average Age
Experienced Board: GKOS's board of directors are considered experienced (5.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.
Top Shareholders
Company Information
Glaukos Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Glaukos Corporation
- Ticker: GKOS
- Exchange: NYSE
- Founded: 1998
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$1.278b
- Shares outstanding: 43.74m
- Website: https://www.glaukos.com
Number of Employees
Location
- Glaukos Corporation
- 229 Avenida Fabricante
- San Clemente
- California
- 92672
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GKOS | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jun 2015 |
| 6GJ | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2015 |
Biography
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. The company’s product pipeline includes iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; iStent SA trabecular micro-bypass system, a two-stent product, which uses a different auto-injection inserter designed for use in a standalone procedure; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. The company markets its products through direct sales force in the United States and other 16 countries, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/04 06:33 |
| End of Day Share Price | 2020/04/03 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.